POSITIVE SELECTION SYSTEMS USING MARKER GENES

这个小企业创新研究第一阶段项目旨在研究开发新化合物的可行性，这些化合物能够利用转化细胞中共同标记基因的表达来控制细胞培养和活组织应用中的细胞生长和特征。如果成功，这项拟议中的研究将提供所需的突破，以推进重组基因的有前途的医疗用途。 在该项目的第一阶段，标记基因技术公司建议建立 通过制备常见生长调节剂、药物和酶激活剂的新的半乳糖苷和头孢菌素结合物，用于给含有β-半乳糖苷酶(LacZ)或氨苄西林耐药(β-内酰胺酶，Amp)基因作为基因融合标记的动物细胞或细菌。这些新的结合物将被用来提供在转化细胞中利用这些融合系统的创新方法--以非破坏性的方式选择转基因细胞。 在第一阶段，将对新的结合物进行体外测试，以确定它们是否能够引起特定和局部的细胞生长改善，并以细胞或组织特定的方式传递活性物质。在第二阶段，这些偶联物将在各种重要的医疗应用中进一步测试。 该项目的成功为细胞选择、遗传疾病的医学干预、癌症治疗的免疫治疗、细胞培养系统中新蛋白质和药物的生物技术生产以及细菌筛选策略等领域开辟了巨大的商业可能性，所制备的结合物可以在这些领域上市。此外，它还为细胞生物学基础研究提供了新的信息和技术。

This Small Business Innovation Research Phase I project aims to investigate the feasibility of developing new compounds capable of utilizing common marker gene expression in transformed cells to control the growth and character of cells in cell culture and live tissue applications. If successful, the proposed research will provide breakthroughs needed to advance the promising medical uses of recombinant genes. In Phase I of this project, Marker Gene Technologies proposes to establish the feasibility of the technology by preparing new galactoside and Cephalosporin conjugates of common growth regulators, drugs and enzyme activators, for administration to animal cells or bacteria that contain either the beta-galactosidase (lacZ) or ampicillin resistance (Beta-lactamase, amp) genes as gene fusion markers. These new conjugates will be used to provide innovative methods of utilizing these fusion systems in transformed cells - to select for transgenic cells in a non-destructive fashion. In Phase I, the new conjugates will be assayed in vitro for their ability to cause specific and localized improvement of cell growth and to deliver the active agents in a cell- or tissue-specific manner. In Phase II, the conjugates will be further tested in a variety of significant medical applications. The success of this project opens up enormous commercial possibilities in the fields of cell selection, medical intervention in genetic diseases, immunotherapy for cancer treatment, biotechnological production of new proteins and drugs in cell-culture systems, and bacterial screening strategies, and the conjugates prepared can be marketed in these areas. In addition, it contributes new information and techniques for basic cell-biology research.